coronavirus treatment

Researchers are reporting some progress in their search for drugs that tamp down the overwhelming immune reaction that can kill a patient with COVID-19.

President Trump will continue to get top-of-the-line medical care for COVID-19 now that he's back at the White House, including the final dose of the new antiviral medication, remdesivir

Scientists are now checking to see if purified blood serum from people who have recovered from COVID-19 might be more than a useful treatment. Perhaps it's a way to prevent disease in someone else.

People with COVID-19 symptoms in March and April were often billed for expensive scans and bloodwork because they didn't qualify back then for a confirmatory coronavirus test. Some are crying foul.

A low-cost anti-inflammatory drug appears to reduce the risk of death in patients with COVID-19. The promising result comes from a large study of therapies being conducted in the U.K.

While only remdesivir has been scientifically shown to help treat COVID-19, it is not a particularly effective drug. More drugs like it and fundamentally different ones are in the pipeline.

The WHO cited a scientific study published last week suggesting that proposed COVID-19 drug hydroxychloroqine may do more harm than good in halting its study to review data.

Prominent figures warned against his musing that UV light or other disinfectants — "by injection inside or almost a cleaning" — may treat the coronavirus. Trump later said he was being "sarcastic."

Pharmaceutical companies GSK and Sanofi are partnering to work on several vaccine candidates to fight the coronavirus.

A drug that's been tested against the coronaviruses that cause MERS and SARS and shown to have valuable antiviral properties appears to be potent against the COVID-19 virus as well.

By renouncing the special status, Gilead Sciences lets go of tax breaks, fee waivers and seven years without generic competition for remdesivir, its experimental COVID-19 treatment.